Johnson & Johnson (JNJ) will beat on EPS and revenue when Q3 earnings are released on Oct. 17th fueled in part by the integration of Actelion and the approval of Tremfya. These beats will occur despite pending talc powder litigation and currency concerns. In theory, JNJ will rally on this news, meaning the time to buy is now.
Analysts are projecting an adjusted diluted earnings per share of $1.80 on revenue of $19.29 billion for JNJ's third quarter. Year over year, that would equate to increases of 7.1% and 8.2%, respectively. That would also be a 1.6% drop in EPS and a 2.4% rise in revenue from the previous quarter. I believe earnings estimates are conservative and will be beaten, driven by the pharmaceutical division. JNJ went so far as to raise guidance during last quarter's earnings call for the remainder of the year.
